BCL3 and colorectal carcinoma: We have previously showed Bcl3 promotes stem-cell phenotypes in CRC cells [14], and therefore wanted to determine whether the combination of DNA damage (cisplatin) and Bcl3 deficiency preferentially targets Lgr5+ intestinal stem cells [37] and/or transit-amplifying progenitor cells.